OCA
FHTX icon

Octagon Capital Advisors’s Foghorn Therapeutics FHTX Stock Holding History

Octagon Capital Advisors’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-69,132
Closed -$911K – 35
2021
Q1 		$911K Buy
+69,132
New +$1.13M 0.34% 28

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Octagon Capital Advisors's FHTX Position: Q2 2021 in Review

Octagon Capital Advisors sold out of Foghorn Therapeutics (FHTX) in Q2 2021, closing a stake of 69,132 shares — an estimated $911K sold.

Octagon Capital Advisors first reported a position in FHTX in Q1 2021 and held it in 1 quarter. The position peaked at $911K in Q1 2021. 39 funds tracked by Wall St. Rank hold FHTX as of Q2 2021.

  • Octagon Capital Advisors reported no remaining Foghorn Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 69,132 Foghorn Therapeutics shares in Q2 2021, an estimated $911K.
  • Octagon Capital Advisors first reported a position in Foghorn Therapeutics in Q1 2021 and held it in 1 quarter.
  • Octagon Capital Advisors's Foghorn Therapeutics position peaked at $911K in Q1 2021.
  • 39 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2021.

Based on Octagon Capital Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.